A look at the abstract on Intercept’s Regenerate trial seems to confirm the earlier topline result, ahead of a full data presentation later today.
Encouraging results from Viking Therapeutics’ lead Nash project have prompted the company to ask how low it can go.
High-profile presentations from the likes of Intercept and Alnylam remain under wraps before Europe’s biggest liver disease conference next month, but the early abstract…
A stumble for Inventiva’s lanifibranor in a rare fibrotic disease could bode ill for its prospects in Nash, and for those of other PPAR agonists.
Check-Cap has a new spin on capsule endoscopy, using X-rays instead of a visual camera. But more compelling clinical data will be necessary if it is to position its…
Novo Nordisk is determined to dominate obesity, but two discontinuations hint that the ride might be rocky.
Gelesis’s weight-loss capsule only hit one of the two co-primary endpoints in its approval trial. Will the FDA be persuaded?
A two-for-one holiday sale is coming for Hetlioz and tradipitant, and Evofem hopes to confirm its contraceptive gel's effectiveness.
Positive phase II data delight investors, but Madrigal Pharmaceuticals leads in the race to market.